GlassScriptPhysician profile
Natalie A Orbach
NPI 1982761300
$10,065.26
in general payments reported to CMS, 2019-2025
47 companies · $2,153 in 2025
The $2,153 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,301 · 2022: $2,350 · 2023: $1,620 · 2024: $1,641 · 2025: $2,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,346 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,346.44 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,478.02 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,366.56 | 2021-2025 | |
| Lilly USA, LLC | $990.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $822.09 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $504.04 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.40 | 2021-2025 | Tradjenta, Synjardy, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $364.61 | 2021-2025 | |
| Pfizer INC. | $333.09 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $316.53 | 2021-2023 | |
| Optinose US, INC. | $297.52 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $249.98 | 2021-2022 | |
| Astellas Pharma US INC | $247.09 | 2021-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.89 | 2021-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $203.78 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $195.40 | 2021-2025 | Capvaxive, Gardasil 9 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Orbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.